How often should patients taking Sabril be monitored?

Patients taking Sabril (vigabatrin) should be monitored every 3 months due to the potential risk of vision loss associated with the medication. Vigabatrin is known for causing irreversible peripheral vision loss in some patients, which necessitates regular eye examinations to ensure that any changes in vision are detected and managed promptly. The 3-month monitoring schedule strikes a balance between ensuring patient safety and allowing for timely intervention should any adverse effects be detected. Monitoring every 3 months provides an opportunity for healthcare providers to assess visual function and determine if the benefits of ongoing treatment outweigh the risks associated with the medication. This approach is critical to safeguarding patients' eye health while they continue their treatment regimen.